Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
08:17am, Sunday, 22'nd Sep 2024
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA approval for Ocrevus Zunovo. Ocrevus Zunovo's co
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20 treatment can
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment
These 12 Stocks are Ripe for a Short Squeeze
10:51am, Tuesday, 10'th Sep 2024
Subscribers to Chart of the Week received this commentary on Sunday, September 8.
Four Biotech Stocks Rally Toward Buy Points As Funds Load Up
01:31pm, Friday, 06'th Sep 2024
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II Phase 3
TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
04:59am, Wednesday, 07'th Aug 2024
TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, a
2 Biotech Stocks Making Moves Today
03:06pm, Tuesday, 06'th Aug 2024
Last month, we took a look at three biotech stocks following a historically bullish month for biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI).
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
09:16am, Tuesday, 06'th Aug 2024
TG Therapeutics (TGTX) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.34 per share a year ago.
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
07:30am, Monday, 05'th Aug 2024
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the s
TG Therapeutics: Pressure On Briumvi To Perform As Share Price Hits Resistance
05:00am, Tuesday, 30'th Jul 2024
Shares of TG Therapeutics had a volatile journey in the last 12 months and have hit resistance levels in the low 20s again. I expect the company to report strong sequential growth of Briumvi, but with
June 2024 New Analysts Cover Uber, TG Therapeutics, CarMax, And More
01:00pm, Tuesday, 02'nd Jul 2024
21 new analysts joined in June and are highlighted today. Each is introduced with some details on their first investment thesis on Seeking Alpha and their background. Analysts cover a range of sectors
The Most Shorted Stocks in June: Hold, Short, or Squeeze?
07:25am, Tuesday, 18'th Jun 2024
Short interest is high and rising in many stocks, setting them up for a squeeze given the proper catalyst. The catalyst for a squeeze could be as simple as Meme stock mania and result in quick gains f
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
07:50am, Friday, 07'th Jun 2024
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Gold
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
07:30am, Monday, 03'rd Jun 2024
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jeff
